We evaluated the effects of baseline IL-8 in the context of anti-tumor T cell activity, as measured by anti-survivin ELISPOT performed on peripheral blood mononuclear cells, and pre-treatment neutrophil-to-lymphocyte ratio. Here, BIRC5 is linked to neoplasm.